A Study of LY2623091 in Participants With High Blood Pressure

NCT02194465 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hypertension

Interventions

DRUG: LY2623091
DRUG: Tadalafil
DRUG: Spironolactone
DRUG: Placebo

Sponsor

Eli Lilly and Company